Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities.
Antibody
Breast cancer
Molecular imaging
Nanobody
Peptide
Pertuzumab
Trastuzumab
Journal
PET clinics
ISSN: 1879-9809
Titre abrégé: PET Clin
Pays: United States
ID NLM: 101260152
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
medline:
4
9
2023
pubmed:
21
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Human epidermal growth factor receptor 2 (HER2) and HER3 provide actionable targets for both therapy and imaging in breast cancer. Further, clinical trials have shown the prognostic impact of receptor status discordance in breast cancer. Intra- and intertumoral heterogeneity of both HER and hormone receptor expression contributes to inherent errors in tissue sampling, and single biopsies are incapable of identifying discordance in biomarker expression. Numerous PET radiopharmaceuticals have been developed to evaluate (or target for therapy) HER2 and HER3 expression. This review seeks to inform on challenges and opportunities in HER2 and HER3 PET imaging in both clinical and preclinical settings.
Identifiants
pubmed: 37339919
pii: S1556-8598(23)00051-2
doi: 10.1016/j.cpet.2023.04.009
pii:
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
ERBB3 protein, human
EC 2.7.10.1
Receptor, ErbB-3
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-555Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.